ராபர்ட் கர்ன் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from ராபர்ட் கர்ன். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In ராபர்ட் கர்ன் Today - Breaking & Trending Today
Lyra Therapeutics to Host Virtual Chronic Rhinosinusitis KOL Event on August 31 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Lyra Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
New data presented includes: - First product candidate found to be effective in non-polyp patients in addition to polyp patients in a clinical trial, based on 100% of patients in both groups achieving SNOT-22 MCID at week 24 with LYR-210 (7500µg group) - - LYR-210 (7500µg) decreased ethmoid opacification at week 24, a measure of disease modification - - LYR-210 (7500µg) reduced the need for rescue medication - - Separately, Lyra also reported an analysis showing that LYR-210 (7500µg) achieved statistically significant improvement across 3 cardinal symptoms at week 24 in the LANTERN study - Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today presented data from its Phase 2 LANTERN study of LYR-210, the company’s lead long-acting product candidate fo ....
Lyra Therapeutics Presents Positive Full Data Set from LANTERN Phase 2 Study of LYR-210 at COSM 2021 Virtual streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Samir Mody as chief commercial officer, while Friedrich Asmus signs on as SVP, clinical development and medical affairs. Meanwhile, the company has also tapped Joel Centeno as SVP, manufacturing, quality and supply chain. Mody comes over from Medtronic, where he was vice president, CRHF strategy, health economics and reimbursement. Asmus previously served as VP of clinical development at ophthalmology biotech ProQR Therapeutics, while Centeno comes over after stints at Boston Scientific, Hologic and AltheaDx. Tamra Adams as chief financial officer, a newly created executive position at the company. Before joining Antios, Adams founded Accounting Concepts, which provided CFO, accounting, and financial services to emerging growth companies in the biopharmaceutical and information technology industries, including Engage Therapeutics. ....